Background Myocardial infarction (MI) is one of the life-threatening coronary-associated
pathologies characterized by sudden cardiac death. The provision of complete insight into …

Improvements in early interventions after acute myocardial infarction (AMI), notably, the
increased use of timely reperfusion therapy, have increased survival dramatically in recent …

Myocardial infarction (MI), as a result of thrombosis or vascular occlusion, is the most
prevalent cause of morbidity and mortality among all cardiovascular diseases. The …

Background ST‐segment–elevation myocardial infarction is associated with an intense
acute inflammatory response and risk of heart failure. We tested whether interleukin‐1 …

Heart failure (HF) has been singled out as an epidemic and is a staggering clinical and
public health problem, associated with significant mortality, morbidity, and healthcare …

Human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) offer a promising cell-
based therapy for myocardial infarction. However, the presence of transitory ventricular …

Current therapies for heart failure after myocardial infarction are limited and non-curative.
Although regenerative approaches are receiving significant attention, clinical efforts that …

Heart failure (HF) is an epidemic in healthcare worldwide, including Asia. It appears that HF
will become more serious in the near future, with the epidemiological transition and ageing …

Heart failure (HF) is a major public health issue, with a prevalence of over 5.8 million in the
USA, and over 23 million worldwide, and rising. The lifetime risk of developing HF is one in …

Importance With improved survival, heart failure (HF) has become a major complication for
individuals with human immunodeficiency virus (HIV) infection. It is unclear if this risk …